In summary, we found that ROS1 mutations were uniquely present in GCB, while TET2 and TRAF3 were only present in non-GCB, and both MYD88 and CD79B mutations appeared only in DLBCL patients. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.